TEST:

TNBCDX®

P=NA | N=9,638 | "This study highlights the clinical value of REVEAL GENOMICS' immune gene combinations, which identify key immune cells such as B-cells and T-cells linked to recurrence, metastasis, and treatment response in HER2-positive (HER2+) and triple-negative breast cancer (TNBC)....Analyzing comprehensive gene expression and clinical data from 9,638 patients across three distinct cohorts, a significant association was observed between immune expression and OS in patients without a documented relapse, independently of cancer subtype, tumor stage, or nodal status. Overall, patients with high immune tumors, characterized by significant immune system activity within its microenvironment, experienced a 41-47% reduction in mortality risk compared to low immune tumors."

The TNBC-DX genomic test effectively predicts pCR to neoadjuvant TCb ± pembrolizumab in TNBC. Notably, the TNBC-DX pCR-high group identifies patients with high sTILs who have a pCR rate exceeding 90% when treated with TCb+P. This study confirms that gene expression and sTILs provide distinct and potentially complementary information for pCR prediction in TNBC.

"REVEAL GENOMICS...today announced both the development and the clinical validation of TNBCDX, the first genomic test designed specifically for patients with early-stage TNBC. This dual milestone will be presented at the ESMO Congress 2024 in Barcelona (Spain)...Across two independent validation studies with 418 patients, the TNBCDX scores showed a strong association with pathological complete response (pCR), distant disease-free survival (DDFS), and overall survival (OS), providing a more refined risk stratification. Notably, the TNBCDX test outperformed tumor-infiltrating lymphocytes (TILs) in predicting both pCR and survival outcomes...The results will be presented at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona (Spain) on Saturday, September 14th."